DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

  • RESET FILTERS

    Special Report: Asthma & COPD Devices

    Device choice has long been a driver for certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United States, device may become an even more important driver of physician choice within respiratory therapies. This report uses a conjoint analysis to examine the relative importance of specific device choice (MDI, DPI, SMI, and nebulizer), device features (e.g., inhalation counter, data capture), and availability of alternatives against the choice of molecule. Both currently available drug/device franchises and hypothetical combinations are considered. Additionally, respiratory nurses are interviewed to assess how patients are introduced to new devices and determine which features are most desirable in clinical practice.

    QUESTIONS ANSWERED

    • How will emerging branded- and AB-rated generics fare against currently available branded inhaler/device combinations?
    • Do pulmonologists prefer therapies available in expanded drug/device franchises, such as the Ellipta or Respimat franchises, or are well-received, stand-alone devices sufficient to drive prescribing?
    • Are certain device types easier for patients to use or for healthcare providers to teach? How important are device features compared to the choice of molecule?
    • What emerging technologies are most likely to drive prescribing? Will pulmonologists value smart technology that enables data capture, or will less complicated devices be preferred?

    DRG’s special topics reports provide quantitative insight into U.S. physician perceptions of key treatment drivers and goals and the current level of unmet need for inhaler technologies. Commercial opportunities are analyzed, and the extent to which emerging therapies and novel device features may capitalize on these opportunities is evaluated.